Who Paid My Doc
Sanjog Mathur
Orthopaedic Surgery of the Spine Columbia, MD Medical Doctor
NPI 1114921053 CMS profile 186825
10700 Charter Dr, Ste 100, Columbia, MD 21044
General payments
$4,773
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sanjog Mathur of Columbia, MD is reported in the CMS Open Payments database as having received $4,773 across 50 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 33rd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,822 | 18 | |
| 2024 | General | $343 | 4 | |
| 2023 | General | $161 | 2 | |
| 2022 | General | $77 | 3 | |
| 2021 | General | $147 | 5 | |
| 2020 | General | $2,054 | 11 | |
| 2019 | General | $168 | 7 |
Beside peers
- Sanjog Mathur
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Sanjog Mathur were reported at $1,822. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Sanjog Mathur | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $168 | $2,106 | $337–$18,608 | $163 |
| 2020 | $2,054 | $1,213 | $156–$15,082 | $114 |
| 2021 | $147 | $1,834 | $271–$15,617 | $132 |
| 2022 | $77 | $2,015 | $320–$17,036 | $149 |
| 2023 | $161 | $1,925 | $336–$14,599 | $160 |
| 2024 | $343 | $2,110 | $341–$12,483 | $164 |
| 2025 | $1,822 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
385
Drug cost
$1,594
Branded share of claims
5.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methylprednisolone | Generic | 93 | $574 | |
| Diclofenac Sodium Er Diclofenac Sodium | Brand | 20 | $284 | |
| Meloxicam | Generic | 120 | $278 | |
| Tramadol Hcl | Generic | 53 | $163 | |
| Oxycodone Hcl | Generic | 38 | $137 | |
| Cyclobenzaprine Hcl | Generic | 16 | $109 | |
| Lorazepam | Generic | 28 | $33 | |
| Diazepam | Generic | 17 | $16 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 138 billing codesPaid by Medicare
$525,320
Medicare patients
656
Services billed
17,508
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 73% | |
| Diabetes | 34% | |
| Osteoporosis | 33% | |
| Ischemic heart disease | 27% | |
| Chronic kidney disease | 27% | |
| Depression | 27% | |
| Cancer | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 155 | 13,180 | $1,336 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 19 | 30 | $231 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 41 | 212 | $149 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 21 | 240 | $70 |
| Injection, cefazolin sodium, 500 mg J0690 | Office | 24 | 27 | $17 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
50 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery of the Spine in Maryland
John Carbone
Orthopaedic Surgery of the Spine · Baltimore, MD
Steven Ludwig
Orthopaedic Surgery of the Spine · Baltimore, MD
Joseph Obrien
Orthopaedic Surgery of the Spine · Bethesda, MD
Paul McAfee
Orthopaedic Surgery of the Spine · Baltimore, MD
Ira Fedder
Orthopaedic Surgery of the Spine · Towson, MD
Scott McGovern
Orthopaedic Surgery of the Spine · Salisbury, MD
Related records
Orthopaedic Surgery of the Spine in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.